Keywords: Hungary, Pharmaceutical environment, R&D targets, Teva, Taxes

Hungary’s pharmaceuticals sector has negative environment for multinationals, says BMI

Article | 14 October 2010

Print This

In Business Monitor International’s Emerging Europe Business Environment Ratings (BER) for the fourth quarter of 2010, Hungary continued to ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in